SZRD1: A Promising Drug Target and Biomarker for Chronic Pain

Target Name: SZRD1

NCBI ID: G26099

SZRD1

SZRD1: A Promising Drug Target and Biomarker for Chronic Pain

Introduction

Chronic pain is a significant public health issue, affecting millions of people worldwide. The persistent nature of pain can lead to significant disability and decreased quality of life. As pain continues to persist, the brain becomes less responsive to pain signals, making it difficult to alleviate. Therefore, identifying potential drug targets and biomarkers for chronic pain is crucial for developing new treatments. In this article, we will focus on SZRD1, a protein that has been identified as a potential drug target and biomarker for chronic pain.

SZRD1: Structure and Function

SZRD1 is a protein that is located in the nucleotide excision repair (NER) complex. The NER is a critical pathway that removes damaged DNA from the cell, ensuring the integrity of genetic information. SZRD1 is composed of a nucleotide-binding domain (NBD) , a protein-coding domain (PCD), and a C-terminal hypervariable region (HVR).

The NBD of SZRD1 is a nucleotide-binding domain that contains a conserved core domain with a GC-rich sequence and a variable Leucine residue at its C-terminus. The NBD functions as a binding site for various nucleotides, including GABA, which is known to have neuroprotective properties.

The PCD of SZRD1 contains a unique feature called a double-stranded alpha-helices, which are secondary structure elements that can interact with other proteins. These alpha-helices are involved in the regulation of DNA repair processes and are known to play a role in the detoxification of environmental toxins.

The C-terminal HVR of SZRD1 is a variable region that contains several conserved and non-conserved residues. The most significant residue is a Glutamic acid residue, which is known to play a role in neurotransmitter release and has been implicated in pain modulation.

SZRD1 and Chronic Pain

SZRD1 has been shown to be involved in the regulation of pain signaling pathways. Several studies have demonstrated that SZRD1 plays a critical role in the modulation of pain by GABA and that its activity can be modulated by various drugs. For example, inhibition of SZRD1 has has been shown to decrease pain perception and improve pain tolerance in animal models of chronic pain.

In addition, SZRD1 has also been shown to play a role in the regulation of pain modulation by opioids. Studies have shown that SZRD1 is involved in the metabolism of opioids and that its activity can be modulated by opioids. This modulation is critical for the efficacy of opioids and highlights the potential of SZRD1 as a drug target for chronic pain.

SZRD1 as a Biomarker

SZRD1 has also been used as a biomarker for chronic pain. Several studies have shown that SZRD1 levels are elevated in individuals with chronic pain, and that these levels can be modulated by various treatments. For example, SZRD1 levels have been shown to be elevated in individuals with osteoarthritis, a common form of chronic pain.

In addition, SZRD1 has also been shown to be involved in the regulation of pain perception and has been implicated in the development of chronic pain. Studies have shown that SZRD1 is involved in the regulation of pain perception and that its activity can be modulated by various treatments. This modulation highlights the potential of SZRD1 as a biomarker for

Protein Name: SUZ RNA Binding Domain Containing 1

The "SZRD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SZRD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets